You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Moodys
Colorcon
Dow
McKesson

Last Updated: February 26, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Dalcetrapib

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for Dalcetrapib?

Dalcetrapib is an investigational drug.

There have been 14 clinical trials for Dalcetrapib. The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 2015.

The most common disease conditions in clinical trials are Coronary Disease, Coronary Artery Disease, and Myocardial Ischemia. The leading clinical trial sponsors are Hoffmann-La Roche, DalCor Pharmaceuticals, and The Montreal Health Innovations Coordinating Center (MHICC).

There are one hundred and fifty-seven US patents protecting this investigational drug and two international patents.

Recent Clinical Trials for Dalcetrapib
TitleSponsorPhase
Effect of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19CovancePhase 2
Effect of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19The Montreal Health Innovations Coordinating Center (MHICC)Phase 2
Effect of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19DalCor PharmaceuticalsPhase 2

See all Dalcetrapib clinical trials

Clinical Trial Summary for Dalcetrapib

Top disease conditions for Dalcetrapib
Top clinical trial sponsors for Dalcetrapib

See all Dalcetrapib clinical trials

US Patents for Dalcetrapib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Dalcetrapib   Start Trial Pharmaceutical compositions with enhanced performance and improved processability HERCULES LLC (Wilmington, DE)   Start Trial
Dalcetrapib   Start Trial Genetic markers for predicting responsiveness to therapy with HDL-raising or HDL mimicking agent Hoffmann-La Roche Inc. (Little Falls, NJ)   Start Trial
Dalcetrapib   Start Trial CETP activity inhibitors Japan Tobacco Inc. (Tokyo, JP)   Start Trial
Dalcetrapib   Start Trial Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals Aventis Pharma Deutschland GmbH (Frankfurt am Main, DE)   Start Trial
Dalcetrapib   Start Trial CETP activity inhibitor Japan Tobacco Inc. (Tokyo, JP)   Start Trial
Dalcetrapib   Start Trial Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals Aventis Pharma Deutschland GmbH (Frankfurt Am Main, DE)   Start Trial
Dalcetrapib   Start Trial Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors Pfizer Inc. (New York, NY)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Dalcetrapib

Drugname Country Document Number Estimated Expiration Related US Patent
Dalcetrapib Brazil BR112015021179 2033-03-01   Start Trial
Dalcetrapib Canada CA2899546 2033-03-01   Start Trial
Dalcetrapib China CN105073783 2033-03-01   Start Trial
Dalcetrapib European Patent Office EP2961775 2033-03-01   Start Trial
Dalcetrapib Japan JP2016510080 2033-03-01   Start Trial
Dalcetrapib Japan JP6456849 2033-03-01   Start Trial
Dalcetrapib South Korea KR20150125655 2033-03-01   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Moodys
Colorcon
Dow
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.